TYRX's first commercially available product is the AIGISRx Antibacterial Envelope for cardiac implantable electronic devices (CIEDs).
The AIGISRx is intended to securely hold a pacemaker or defibrillator in place to create a stable environment.
More information can be found at AIGISRx Antibacterial Envelope.
News & Events
New Prospective Study Data Demonstrate the AIGISRx is Associated with Extremely Low 90-Day CIED Infection Rates in Patients at High Risk for CIED Infection
• New Citadel / Centurion prospective study data presented on 1,000 patients with ICD & CRT replacement with AIGISRx at Heart Rhythm 2013 Scientific Sessions Late-breaking Clinical Trials Session by Dr. Charles A. Henrikson, Chief of Electrophysiology at Oregon Health & Science University
• 95% fewer major CIED infections in study cohort vs. pre-defined published control cohort of ICD & CRT replacement procedures (0.1% vs. 1.88%; P<0.001) (Gould et al. JAMA 2006, 295(16); 1907-1911)
New Study from Valley Health System Shows 70% Reduction in CIED Infections with AIGISRx in Patients at High Risk for CIED Infection
• New clinical study comparing device infection in CIED patients with AIGISRx, to site and risk-matched patients without AIGISRx was presented at the Heart Rhythm 2013 Scientific Sessions by Dr. Suneet Mittal, the Chief of Electrophysiology at the Valley Health System of New York & New Jersey, Associate Clinical Professor of Medicine at Columbia University
• In propensity score matched cohorts there were significantly fewer CIED infections in the cohort with the AIGISRx Envelope (3 infections / 275 patients (1.1%) vs. 10 infections / 275 patients without the AIGISRx Envelope (3.7%); P=0.048)
• Use of AIGISRx Envelope was associated with a significant 70% reduction in CIED infections in patients at high risk for device infection
Nearly 50% of Patients with CIED Infections Don't Survive Beyond 3 Years
• New Mayo Clinic Study of long-term mortality of 200, 219 Medicare fee-for-service patients undergoing cardiac device procedures presented at Heart Rhythm 2013
• Patients with pacemaker infection had 54% mortality vs. 33% without pacemaker infection
• Patients with ICD infection had 48% mortality vs. 32% without ICD infection
• Patients with CRT infection mortality vs. 37% with CRT infection
Vanderbilt Study Shows 87% Decline in CIED Infections with AIGISRx Antibacterial Envelope
• Study of patients at high risk for CIED infection published in journal of Pacing and Electrophisiology (PACE), March 2013
• Results show 0.4% CIED infection rate in patients who received AIGISRx implants, compared to 3.0% in control group that did not receive AIGISRx implants (P=0.04)